ESTETROL WITH DROSPIRENONE
Information current as at: 1 May 2026
Submission Details
- Brand name:
-
- Nextstellis®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Contraception
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New PBS listing (Category 2)
- Comment:
- --
- Submission sponsor:
- MAYNE PHARMA INTERNATIONAL PTY LTD
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - March 2025 PBAC meeting
-
Opportunity for consumer comment: - Open 27/11/2024 and close 29/01/2025 (see PBS Website)
-
PBAC meeting: - Held on 12/03/2025
-
Lodgement of required documentation: - 27/05/2025
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 22/07/2025
-
Status:
- Finalised
-
Government processes: - Commenced on 01/08/2025
-
Medicine listed on the PBS: - 01/10/2025 (see PBS schedule)
PBAC Outcome
Case ID: a980
Page last updated: 31 March 2026

